Some triple-negative breast cancer tumors may benefit from JAK
inhibitors, a class of anti-inflammatory drugs currently used to treat rheumatoid
arthritis, according to research in Cell Reports.
These tumors rely on an antiviral pathway related to inflammation,
widely recognized for roles in cancer, rheumatoid arthritis, and other
inflammatory diseases. Biologically, they have mutations of the proteins p53
and ARF.
"There are JAK inhibitors in use for rheumatoid arthritis
and being tested against a number of other conditions,"
said senior author Jason D. Weber, PhD, of the Washington University School of Medicine in St. Louis, Missouri
For more information, check out my book, Surviving Triple-Negative Breast Cancer. You can get a free signed copy just by donating $25 to this site. Click the Donate button on the right to donate through PayPal. You'll then get an email from me asking how you want your book signed and where you want it sent. Or you can buy the book directly without a donation. Thanks! And hugs.
2 comments:
Are there clinical trials for the anti inflamatory gene ?
I'd check with Washington University, where this research was done. They might know of studies in the pipeline. Also, Breastcancer.org has a list of clinical trials at https://www.breastcancertrials.org/bct_nation/browse_trials.seam. And I have a link to news on clinical trials on this blog--look in the right hand column.
Post a Comment